激酶抑制剂-话题@MedSci

#激酶抑制剂#

80篇内容 | 3564人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2039888, encodeId=947d2039888dc, content=<a href='/topic/show?id=f7526685963' target=_blank style='color:#2F92EE;'>#激酶抑制剂#</a>, objectTitle=JCC： JAK激酶抑制剂Peficitinib在治疗中重度UC中有良好效果, objectType=article, longId=153224, objectId=b6d91532243b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b6d91532243b, replyNumber=0, likeNumber=75, createdTime=2019-04-12, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b6d91532243b, moduleTitle=JCC： JAK激酶抑制剂Peficitinib在治疗中重度UC中有良好效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b6d91532243b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2039889, encodeId=daf2203988977, content=<a href='/topic/show?id=f7526685963' target=_blank style='color:#2F92EE;'>#激酶抑制剂#</a>, objectTitle=CLIN CANCER RES：cyclin E过表达使三阴性乳腺癌对Wee1激酶抑制剂敏感, objectType=article, longId=156475, objectId=47b21564e5ad, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=47b21564e5ad, replyNumber=0, likeNumber=83, createdTime=2019-05-12, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=47b21564e5ad, moduleTitle=CLIN CANCER RES：cyclin E过表达使三阴性乳腺癌对Wee1激酶抑制剂敏感, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=47b21564e5ad)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2039893, encodeId=ec832039893e1, content=<a href='/topic/show?id=f7526685963' target=_blank style='color:#2F92EE;'>#激酶抑制剂#</a>, objectTitle=NICE推荐BRAF激酶抑制剂与MEK抑制剂联合治疗BRAF V600突变的黑素瘤患者, objectType=article, longId=158891, objectId=8a5b15889101, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8a5b15889101, replyNumber=0, likeNumber=95, createdTime=2019-05-05, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8a5b15889101, moduleTitle=NICE推荐BRAF激酶抑制剂与MEK抑制剂联合治疗BRAF V600突变的黑素瘤患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8a5b15889101)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2039890, encodeId=04b02039890fc, content=<a href='/topic/show?id=f7526685963' target=_blank style='color:#2F92EE;'>#激酶抑制剂#</a>, objectTitle=2018 中国共识：胃肠道间质瘤应用酪氨酸激酶抑制剂的相关副作用（英文版）, objectType=article, longId=157357, objectId=d46815e35719, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d46815e35719, replyNumber=0, likeNumber=47, createdTime=2019-08-28, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d46815e35719, moduleTitle=2018 中国共识：胃肠道间质瘤应用酪氨酸激酶抑制剂的相关副作用（英文版）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d46815e35719)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2039882, encodeId=eb34203988276, content=<a href='/topic/show?id=f7526685963' target=_blank style='color:#2F92EE;'>#激酶抑制剂#</a>, objectTitle=粘着斑激酶抑制剂克服了骨髓微环境中套细胞淋巴瘤对伊布替尼的耐药性, objectType=article, longId=133938, objectId=84b21339380a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=84b21339380a, replyNumber=0, likeNumber=84, createdTime=2019-02-19, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=84b21339380a, moduleTitle=粘着斑激酶抑制剂克服了骨髓微环境中套细胞淋巴瘤对伊布替尼的耐药性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=84b21339380a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2039891, encodeId=4bd12039891f5, content=<a href='/topic/show?id=f7526685963' target=_blank style='color:#2F92EE;'>#激酶抑制剂#</a>, objectTitle=J Med Chem:合肥研究院研发出针对急性髓性白血病FLT3-ITD突变选择性的第三代新型FLT3激酶抑制剂, objectType=article, longId=157734, objectId=5a8f15e7340d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5a8f15e7340d, replyNumber=0, likeNumber=99, createdTime=2019-03-05, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5a8f15e7340d, moduleTitle=J Med Chem:合肥研究院研发出针对急性髓性白血病FLT3-ITD突变选择性的第三代新型FLT3激酶抑制剂, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5a8f15e7340d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2039885, encodeId=d3b9203988542, content=<a href='/topic/show?id=f7526685963' target=_blank style='color:#2F92EE;'>#激酶抑制剂#</a>, objectTitle=2018 法国慢性粒细胞白血病研究组实践建议：酪氨酸激酶抑制剂治疗慢性粒细胞白血病的停药, objectType=article, longId=137600, objectId=977913e600e6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=977913e600e6, replyNumber=0, likeNumber=49, createdTime=2018-10-12, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=977913e600e6, moduleTitle=2018 法国慢性粒细胞白血病研究组实践建议：酪氨酸激酶抑制剂治疗慢性粒细胞白血病的停药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=977913e600e6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2039883, encodeId=4a712039883bd, content=<a href='/topic/show?id=f7526685963' target=_blank style='color:#2F92EE;'>#激酶抑制剂#</a>, objectTitle=辉瑞酪氨酸激酶抑制剂Inlyta治疗早期肾癌的临床三期试验惨遭失败, objectType=article, longId=135429, objectId=c9ea1354297d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c9ea1354297d, replyNumber=0, likeNumber=94, createdTime=2019-02-24, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c9ea1354297d, moduleTitle=辉瑞酪氨酸激酶抑制剂Inlyta治疗早期肾癌的临床三期试验惨遭失败, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c9ea1354297d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2039876, encodeId=a62b20398e64a, content=<a href='/topic/show?id=f7526685963' target=_blank style='color:#2F92EE;'>#激酶抑制剂#</a>, objectTitle=Blood：在Ph样急性淋巴细胞白血病中发现一新的与酪氨酸激酶抑制剂耐药性直接相关的PDGFRB突变, objectType=article, longId=129567, objectId=985a12956e3b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=985a12956e3b, replyNumber=0, likeNumber=82, createdTime=2018-12-31, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=985a12956e3b, moduleTitle=Blood：在Ph样急性淋巴细胞白血病中发现一新的与酪氨酸激酶抑制剂耐药性直接相关的PDGFRB突变, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=985a12956e3b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2039875, encodeId=6ed820398e58d, content=<a href='/topic/show?id=f7526685963' target=_blank style='color:#2F92EE;'>#激酶抑制剂#</a>, objectTitle=EUR J Cancer：用以晚期实体瘤患者治疗的选择性MET酪氨酸激酶抑制剂SAR125844的I期临床, objectType=article, longId=124748, objectId=f1cf124e4855, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f1cf124e4855, replyNumber=0, likeNumber=75, createdTime=2018-03-23, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f1cf124e4855, moduleTitle=EUR J Cancer：用以晚期实体瘤患者治疗的选择性MET酪氨酸激酶抑制剂SAR125844的I期临床, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f1cf124e4855)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2039884, encodeId=8eed203988482, content=<a href='/topic/show?id=f7526685963' target=_blank style='color:#2F92EE;'>#激酶抑制剂#</a>, objectTitle=Lancet Oncol：慢性髓系白血病患者停止酪氨酸激酶抑制剂治疗的先决条件及对疾病控制的影响, objectType=article, longId=137517, objectId=f72b13e517e1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f72b13e517e1, replyNumber=0, likeNumber=74, createdTime=2019-01-13, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f72b13e517e1, moduleTitle=Lancet Oncol：慢性髓系白血病患者停止酪氨酸激酶抑制剂治疗的先决条件及对疾病控制的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f72b13e517e1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2039879, encodeId=233620398e9cb, content=<a href='/topic/show?id=f7526685963' target=_blank style='color:#2F92EE;'>#激酶抑制剂#</a>, objectTitle=Blood：口服Bruton酪氨酸激酶抑制剂可选择性阻滞动脉粥样硬化斑块触发的血栓形成, objectType=article, longId=133117, objectId=a4d213311e96, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a4d213311e96, replyNumber=0, likeNumber=82, createdTime=2018-09-06, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a4d213311e96, moduleTitle=Blood：口服Bruton酪氨酸激酶抑制剂可选择性阻滞动脉粥样硬化斑块触发的血栓形成, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a4d213311e96)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2039881, encodeId=6de92039881f1, content=<a href='/topic/show?id=f7526685963' target=_blank style='color:#2F92EE;'>#激酶抑制剂#</a>, objectTitle=Blood：Pan-SRC激酶抑制剂可阻断非霍奇金淋巴瘤的B细胞受体致瘤信号转导, objectType=article, longId=133361, objectId=5e4b133361e8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5e4b133361e8, replyNumber=0, likeNumber=127, createdTime=2018-11-02, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5e4b133361e8, moduleTitle=Blood：Pan-SRC激酶抑制剂可阻断非霍奇金淋巴瘤的B细胞受体致瘤信号转导, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5e4b133361e8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2039880, encodeId=c1992039880b2, content=<a href='/topic/show?id=f7526685963' target=_blank style='color:#2F92EE;'>#激酶抑制剂#</a>, objectTitle=Nat Rev Drug Discov：激酶抑制剂药物路在何方？, objectType=article, longId=133132, objectId=ca02133132ba, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ca02133132ba, replyNumber=0, likeNumber=77, createdTime=2018-11-16, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ca02133132ba, moduleTitle=Nat Rev Drug Discov：激酶抑制剂药物路在何方？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ca02133132ba)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2039886, encodeId=cb682039886b1, content=<a href='/topic/show?id=f7526685963' target=_blank style='color:#2F92EE;'>#激酶抑制剂#</a>, objectTitle=Blood：酪氨酸激酶抑制剂诱导的DNA修复缺陷使FLT3(ITD)阳性的白血病细胞对PARP1抑制剂治疗敏感, objectType=article, longId=138866, objectId=681b1388668c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=681b1388668c, replyNumber=0, likeNumber=69, createdTime=2018-06-14, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=681b1388668c, moduleTitle=Blood：酪氨酸激酶抑制剂诱导的DNA修复缺陷使FLT3(ITD)阳性的白血病细胞对PARP1抑制剂治疗敏感, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=681b1388668c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2039887, encodeId=3a6f203988ecd, content=<a href='/topic/show?id=f7526685963' target=_blank style='color:#2F92EE;'>#激酶抑制剂#</a>, objectTitle=J Periodontol: 人牙龈成纤维细胞中rho-激酶抑制剂y-27632通过阻断p38MAPK和 NF-κB通路下调lps诱导的IL-6和IL-8的分泌, objectType=article, longId=139947, objectId=bf6513994e73, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bf6513994e73, replyNumber=0, likeNumber=103, createdTime=2018-08-17, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bf6513994e73, moduleTitle=J Periodontol: 人牙龈成纤维细胞中rho-激酶抑制剂y-27632通过阻断p38MAPK和 NF-κB通路下调lps诱导的IL-6和IL-8的分泌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bf6513994e73)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2039871, encodeId=de9020398e155, content=<a href='/topic/show?id=f7526685963' target=_blank style='color:#2F92EE;'>#激酶抑制剂#</a>, objectTitle=J Am Acad Dermatol：使用酪氨酸激酶抑制剂治疗白癜风的关键——光照, objectType=article, longId=111207, objectId=097a11120e7b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=097a11120e7b, replyNumber=0, likeNumber=96, createdTime=2017-11-08, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=097a11120e7b, moduleTitle=J Am Acad Dermatol：使用酪氨酸激酶抑制剂治疗白癜风的关键——光照, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=097a11120e7b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2039867, encodeId=7e95203986e0f, content=<a href='/topic/show?id=f7526685963' target=_blank style='color:#2F92EE;'>#激酶抑制剂#</a>, objectTitle=JAHA：IκB激酶抑制剂能显著改善急性肾损伤的肾功能恢复, objectType=article, longId=104681, objectId=007b1046815c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=007b1046815c, replyNumber=0, likeNumber=109, createdTime=2018-05-21, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=007b1046815c, moduleTitle=JAHA：IκB激酶抑制剂能显著改善急性肾损伤的肾功能恢复, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=007b1046815c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2039872, encodeId=6ea620398e2fa, content=<a href='/topic/show?id=f7526685963' target=_blank style='color:#2F92EE;'>#激酶抑制剂#</a>, objectTitle=2017 实践建议：肿瘤治疗中激酶抑制剂治疗药物监测, objectType=article, longId=112056, objectId=ec5a1120564b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ec5a1120564b, replyNumber=0, likeNumber=40, createdTime=2018-07-20, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ec5a1120564b, moduleTitle=2017 实践建议：肿瘤治疗中激酶抑制剂治疗药物监测, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ec5a1120564b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2039878, encodeId=ed3320398e859, content=<a href='/topic/show?id=f7526685963' target=_blank style='color:#2F92EE;'>#激酶抑制剂#</a>, objectTitle=Lancet oncol：尼洛替尼（nilotinib），CSF1R酪氨酸激酶抑制剂，可控制色素性绒毛结节性滑膜炎患者的病程进展, objectType=article, longId=133036, objectId=740813303624, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=740813303624, replyNumber=0, likeNumber=46, createdTime=2018-06-23, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=740813303624, moduleTitle=Lancet oncol：尼洛替尼（nilotinib），CSF1R酪氨酸激酶抑制剂，可控制色素性绒毛结节性滑膜炎患者的病程进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=740813303624)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

激酶抑制剂

2020-05-29

smartjoy (审核中...)

前往app查看评论内容

#激酶抑制剂#

JCC： JAK激酶抑制剂Peficitinib在治疗中重度UC中有良好效果

2019-04-12

smartjoy (审核中...)

前往app查看评论内容

#激酶抑制剂#

CLIN CANCER RES：cyclin E过表达使三阴性乳腺癌对Wee1激酶抑制剂敏感

2019-05-12

smartjoy (审核中...)

前往app查看评论内容

#激酶抑制剂#

NICE推荐BRAF激酶抑制剂与MEK抑制剂联合治疗BRAF V600突变的黑素瘤患者

2019-05-05

smartjoy (审核中...)

前往app查看评论内容

#激酶抑制剂#

2018 中国共识：胃肠道间质瘤应用酪氨酸激酶抑制剂的相关副作用（英文版）

2019-08-28

smartjoy (审核中...)

前往app查看评论内容

#激酶抑制剂#

粘着斑激酶抑制剂克服了骨髓微环境中套细胞淋巴瘤对伊布替尼的耐药性

2019-02-19

smartjoy (审核中...)

前往app查看评论内容

#激酶抑制剂#

J Med Chem:合肥研究院研发出针对急性髓性白血病FLT3-ITD突变选择性的第三代新型FLT3激酶抑制剂

2019-03-05

smartjoy (审核中...)

前往app查看评论内容

#激酶抑制剂#

2018 法国慢性粒细胞白血病研究组实践建议：酪氨酸激酶抑制剂治疗慢性粒细胞白血病的停药

2018-10-12

smartjoy (审核中...)

前往app查看评论内容

#激酶抑制剂#

辉瑞酪氨酸激酶抑制剂Inlyta治疗早期肾癌的临床三期试验惨遭失败

2019-02-24

smartjoy (审核中...)

前往app查看评论内容

#激酶抑制剂#

Blood：在Ph样急性淋巴细胞白血病中发现一新的与酪氨酸激酶抑制剂耐药性直接相关的PDGFRB突变

2018-12-31

smartjoy (审核中...)

前往app查看评论内容

#激酶抑制剂#

EUR J Cancer：用以晚期实体瘤患者治疗的选择性MET酪氨酸激酶抑制剂SAR125844的I期临床

2018-03-23

smartjoy (审核中...)

前往app查看评论内容

#激酶抑制剂#

Lancet Oncol：慢性髓系白血病患者停止酪氨酸激酶抑制剂治疗的先决条件及对疾病控制的影响

2019-01-13

smartjoy (审核中...)

前往app查看评论内容

#激酶抑制剂#

Blood：口服Bruton酪氨酸激酶抑制剂可选择性阻滞动脉粥样硬化斑块触发的血栓形成

2018-09-06

smartjoy (审核中...)

前往app查看评论内容

#激酶抑制剂#

Blood：Pan-SRC激酶抑制剂可阻断非霍奇金淋巴瘤的B细胞受体致瘤信号转导

2018-11-02

smartjoy (审核中...)

前往app查看评论内容

#激酶抑制剂#

Nat Rev Drug Discov：激酶抑制剂药物路在何方？

2018-11-16

smartjoy (审核中...)

前往app查看评论内容

#激酶抑制剂#

Blood：酪氨酸激酶抑制剂诱导的DNA修复缺陷使FLT3(ITD)阳性的白血病细胞对PARP1抑制剂治疗敏感

2018-06-14

smartjoy (审核中...)

前往app查看评论内容

#激酶抑制剂#

J Periodontol: 人牙龈成纤维细胞中rho-激酶抑制剂y-27632通过阻断p38MAPK和 NF-κB通路下调lps诱导的IL-6和IL-8的分泌

2018-08-17

smartjoy (审核中...)

前往app查看评论内容

#激酶抑制剂#

J Am Acad Dermatol：使用酪氨酸激酶抑制剂治疗白癜风的关键——光照

2017-11-08

smartjoy (审核中...)

前往app查看评论内容

#激酶抑制剂#

JAHA：IκB激酶抑制剂能显著改善急性肾损伤的肾功能恢复

2018-05-21

smartjoy (审核中...)

前往app查看评论内容

#激酶抑制剂#

2017 实践建议：肿瘤治疗中激酶抑制剂治疗药物监测

2018-07-20

smartjoy (审核中...)

前往app查看评论内容

#激酶抑制剂#

Lancet oncol：尼洛替尼（nilotinib），CSF1R酪氨酸激酶抑制剂，可控制色素性绒毛结节性滑膜炎患者的病程进展

2018-06-23

科室
- - 订阅+
  - 更多科室
工具
服务